Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

重组带状疱疹疫苗（葛兰素史克）

Report date: 2026/04/09 20:00:21

Base Information

Drug NameZoster vaccine recombinant, adjuvanted (GlaxoSmithKline)
Drug Alias Name水痘-带状疱疹疫苗 - 葛兰素史克herpes zoster vaccine (recombinant, adjuvanted)recombinant adjuvanted Herpes Zoster vaccineVaricella zoster vaccine (GlaxoSmithKline)Herpes zoster vaccine candidate (Hz/su) +[14] 
ClassificationVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRejection of renal transplantationKidney Failure, ChronicRenal Insufficiency +[11] 
Global Approved IndicationsNeuralgia, PostherpeticHerpes Zoster
Approved Indications in ChinaHerpes Zoster
Original Approved Country/TerritoryUnited States
Original Approved Date2017/10/20
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesJapan VaccineGlaxosmithkline PlcUniversity Of Rochester +[8] 
Inactive CompaniesLoyola UniversityNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsRejection of renal transplantationKidney Failure, ChronicRenal Insufficiency +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeJ07BK03
Related LinksWikipediaDrugBankKEGG